Ovarian Cancer Diagnosis and Treatment

SEP 8, 2026 · JOURNAL ARTICLE

Prognostic and therapeutic implications of BRCA1 and BRCA2 mutations in ovarian cancer

Frontiers in Oncology

A literature review synthesizing evidence on BRCA1/2 as prognostic and predictive biomarkers in ovarian cancer, providing clinical recommendations for testing and treatment selection rather than reporting original trial data.

SEP 8, 2026 · JOURNAL ARTICLE

Beyond CA-125: circulating cell-free DNA as the next-generation biomarker in ovarian malignancy

BMC Cancer

A prospective case–control study of modest size (150 participants) with clear separation between groups and strong ROC performance for a candidate biomarker, but surrogate endpoints (AUC, survival association) rather than a clinical trial of intervention, requiring confirmation in independent cohorts.

SEP 7, 2026 · JOURNAL ARTICLE

The evolving role of open abdominal surgery in gynecological malignancies in the era of minimally invasive and precision oncology

World Journal of Surgical Oncology

A narrative review synthesizing current literature on surgical approaches in gynecological malignancies, offering expert consensus on the continuing role of open surgery alongside modern alternatives rather than reporting new empirical data.

SEP 4, 2026 · JOURNAL ARTICLE

Applications of Olaparib and Durvalumab Combination Therapy for a Founder BRCA1 Mutation in the Chinese Han Population: A Literature Review

Scholarly Review .

A literature review synthesizing current evidence on PARP inhibitor and immunotherapy combinations for BRCA-mutated cancers, offering clinical perspective rather than reporting original trial data.

AUG 18, 2026 · JOURNAL ARTICLE

Ovarian Cancer in Women Living With HIV: Epidemiology, Mechanisms, and Clinical Management

Journal of Immunology and Clinical Microbiology

A narrative review synthesizing heterogeneous observational studies with acknowledged limited and incompletely understood evidence; raises questions about HIV–ovarian cancer association rather than establishing a definitive answer.

AUG 17, 2026 · JOURNAL ARTICLE

Pamiparib plus surufatinib with ctDNA monitoring in platinum-resistant ovarian cancer after PARP inhibitor progression: a phase Ib/II trial (POST-PARPi)

BMC Medicine

Phase Ib/II trial showing modest efficacy (46.7% 6-month PFS) with manageable toxicity in a treatment-refractory population, but limited by small sample size, low objective response rate, and single-arm design without comparator.

AUG 15, 2026 · JOURNAL ARTICLE

Breast metastasis from BRCA1-mutated ovarian cancer: response to parp inhibition and a potential lymphatic route

BMC Women S Health

Single case report documenting an unusual metastatic pattern and therapeutic response; raises mechanistic questions about lymphatic spread and HER2 conversion but lacks comparative data or generalizable evidence.

AUG 14, 2026 · JOURNAL ARTICLE

Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies

Cancers

A narrative review synthesizing preclinical and clinical evidence across multiple therapeutic modalities for ovarian cancer, identifying mature strategies (PARP inhibitors, antiangiogenic agents) and early-stage approaches, intended to guide therapeutic selection and future research directions.